Filing Flows › Xeris Biopharma Holdings (XERS) › Q3 2026 › vs Q2 2026
Xeris Biopharma Holdings (XERS) Q3 2026 vs Q2 2026 (quarter over quarter)
Xeris Biopharma Holdings's revenue rose $15.1M (+16%) from $92.1M in Q2 2026 to $107M in Q3 2026. The biggest changes: Product revenue, net +$15.3M (+17%); Royalty, contract and other revenue −$138K (-13%). Operating margin 15.8% against 5.6% (+10.2 pts).
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 15.8% | 5.6% | +10.2 pts |
| Net margin | 10.5% | -33.8% | +44.3 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Recorlev | $71.5M | $56.8M | $14.8M | +26% |
| Gvoke | $21.7M | $22.5M | −$843K | -4% |
| Keveyis | $13.0M | $11.7M | $1.3M | +12% |
| Product revenue, net | $106M | $91.0M | $15.3M | +17% |
| Royalty, contract and other revenue | $958K | $1.1M | −$138K | -13% |
| Revenue | $107M | $92.1M | $15.1M | +16% |
| Operating profit | $16.9M | $5.2M | $11.7M | +227% |
| Costs & expenses | $90.3M | $86.9M | $3.4M | +4% |
| Pre-tax earnings | $11.3M | −$31.1M | $42.4M | — |
| Other expense, net | $5.6M | $36.3M | −$30.6M | -84% |
| Cost of revenue | $12.4M | $12.5M | −$83K | -0.7% |
| Research & development | $11.1M | $10.7M | $389K | +4% |
| SG&A | $64.1M | $61.0M | $3.1M | +5% |
| Other operating costs | $2.7M | $2.7M | $0 | 0% |
| Net earnings | $11.3M | −$31.1M | $42.4M | — |
| Depreciation & amortization | $300K | $323K | −$23K | -7% |
| Share-based compensation | $10.8M | $11.1M | −$264K | -2% |
| Working capital & other | $13.1M | $28.0M | −$14.9M | -53% |
| Operating cash flow | $35.5M | $8.3M | $27.2M | +329% |
Questions
How much did Xeris Biopharma Holdings's revenue grow quarter over quarter in Q3 2026?
Xeris Biopharma Holdings's revenue rose $15.1M (+16%) from $92.1M in Q2 2026 to $107M in Q3 2026.
What drove Xeris Biopharma Holdings's revenue change in Q3 2026?
Product revenue, net +$15.3M (+17%); Royalty, contract and other revenue −$138K (-13%).